Russia Pharma and Healthcare Report 2018/2019

  • ID: 4483553
  • Report
  • Region: Russia
  • 80 pages
  • EMIS, A Euromoney Institutional Investor Company
1 of 5
Pharmaceutical Sales in Russia Declined for the Third Straight Year in 2016, While the Government's Protectionist Policy Boosted Domestic Output

FEATURED COMPANIES

  • OJSC Katren
  • PJSC OTCPharm
  • PJSC Pharmstandard
  • Protek Group
  • Veropharm
  • MORE
This report provides a complete and detailed analysis of the pharma and healthcare sector for Russia. The author presents in-depth business intelligence in a standard format across countries and regions, providing a balanced mix between analysis and data.

What this report allows you to do:
  • Understand the key elements at play in the pharma and healthcare sector in Russia
  • Assess market for growth in the sector
  • View key data on healthcare spending and health insurance in Russia
  • Crystallise the forces both driving and restraining this sector in Russia
  • Build a complete perspective on sector trade, investment and employment
  • Understand the competitive landscape and who the major players are
  • View M&A activity and major deals
  • Gain an understanding of the regulatory environment for the sector in Russia
  • Build a clear picture of trends and issues for sub-sectors (medical institutions, pharmaceuticals manufacturing and distribution channels).
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • OJSC Katren
  • PJSC OTCPharm
  • PJSC Pharmstandard
  • Protek Group
  • Veropharm
  • MORE
1. Executive Summary
  • Sector in Numbers
  • Sector Overview
  • Sector Snapshot
  • Sector Outlook
  • Subsector Outlook
  • Driving Forces
  • Restraining Forces
2. Sector in Focus
  • Main Economic Indicators
  • Main Sector Indicators
  • Healthcare Expenditure
  • Public Healthcare Expenditure
  • Private Healthcare Expenditure
  • Healthcare Expenditure of Households
  • External Trade
  • Imports
  • Exports
  • Prices
  • Enterprises
  • Employment and Wages
  • Healthcare Resources
  • Investment
3. Competitive Landscape
  • Timeline Russia Pharma & Healthcare
  • Highlights
  • Main Players
  • Top M&A Deals
  • M&A Activity, 2016-2017
4. Companies in Focus
  • Protek Group
  • PJSC Pharmstandard
  • OJSC Katren
  • PJSC OTCPharm
  • Veropharm
5. Regulatory Environment
  • Key Bodies
  • Government Policy
  • Pharma 2020 Programme
6. Pharmaceuticals
  • Focus Point - Retail Sales of Medicines
  • Highlights
  • Main events
  • Production
  • Sales
  • OTC Sales
  • To Pharmaceutical Distributors
  • External Trade
  • Imports
  • Exports
7. Medical Equipment
  • Highlights
  • Main Events
  • Production
  • Sales
  • Public Procurement
  • Imports
  • Exports
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • OJSC Katren
  • PJSC OTCPharm
  • PJSC Pharmstandard
  • Protek Group
  • Veropharm
  • MORE
Russia’s healthcare and pharmaceutical sector was badly affected by the 2015-2016 recession, which resulted in a sharp drop in government spending, while the weak rouble and high inflation cut into households’ disposable incomes. Though healthcare spending continued to increase in local currency terms, it slumped to less than two-thirds of its 2014 level in terms of US dollars. Pharmaceutical (pharma) sales declined for the third straight year in 2016. However, the government’s protectionist policy helped boost domestic production of pharmaceuticals, with output growing at double-digit rates in both 2015 and 2016.
Note: Product cover images may vary from those shown
5 of 5
  • Protek Group
  • PJSC Pharmstandard
  • OJSC Katren
  • PJSC OTCPharm
  • Veropharm
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll